Overview

Location [1]
7q21.2
Pathway
Cell cycle control
Protein [2]
Cyclin-dependent kinase 6
Synonyms [1]
PLSTIRE, MCPH12

Cyclin-dependent kinase 4 (CDK6) is a gene that encodes a protein that is a member of the cyclin-dependent protein kinase family. The protein functions in the progression of the cell cycle at from G1 to S phase and the regulation of RB1. Fusions, missense, nonsense, and silent mutations are observed in cancers such as endometrial cancer, intestinal cancer, and stomach cancer.

CDK6 is altered in 0.82% of all cancers with lung adenocarcinoma, breast invasive ductal carcinoma, colon adenocarcinoma, conventional glioblastoma multiforme, and esophageal adenocarcinoma having the greatest prevalence of alterations [3].

CDK6 GENIE Cases - Top Diseases

The most common alterations in CDK6 are CDK6 Amplification (0.55%), CDK6 Mutation (0.39%), CDK6 Loss (0.02%), CDK6 R220C (0.01%), and CDK6 I159M (0.01%) [3].

CDK6 GENIE Cases - Top Alterations

Significance of CDK6 in Diseases

Malignant Solid Tumor +

Malignant Glioma +

Breast Carcinoma +

Medulloblastoma +

Medulloblastoma, Non-WNT/Non-SHH +

Multiple Myeloma +

Esophageal Carcinoma +

Glioblastoma +

Colorectal Carcinoma +

Ovarian Carcinoma +

Central Nervous System Embryonal Neoplasm +

Central Nervous System Ganglioneuroblastoma +

Central Nervous System Neuroblastoma +

Desmoplastic/Nodular Medulloblastoma +

Head And Neck Squamous Cell Carcinoma +

Large Cell/Anaplastic Medulloblastoma +

Medulloblastoma With Extensive Nodularity +

Medulloblastoma, SHH-Activated +

Medulloblastoma, WNT-Activated +

Medulloepithelioma +

Non-Hodgkin Lymphoma +

Gallbladder Carcinoma +

Gastric Adenocarcinoma +

Gastric Carcinoma +

Diffuse Glioma +

Endometrial Endometrioid Adenocarcinoma +

Pancreatic Carcinoma +

Melanoma +

Bile Duct Carcinoma +

Lymphoma +

Bladder Carcinoma +

Malignant Uterine Neoplasm +

Cancer +

Lung Carcinoma +

Non-Small Cell Lung Carcinoma +

Ovarian Epithelial Tumor +

Adenocarcinoma Of The Gastroesophageal Junction +

Anaplastic Astrocytoma +

Anaplastic Astrocytoma, IDH-Mutant +

Anaplastic Ependymoma +

Anaplastic Oligodendroglioma +

Anaplastic Oligodendroglioma, IDH-Mutant And 1p/19q-Codeleted +

Anaplastic Pleomorphic Xanthoastrocytoma +

Atypical Teratoid/Rhabdoid Tumor +

B-Cell Non-Hodgkin Lymphoma +

Bronchogenic Carcinoma +

Cervical Carcinoma +

Chondrosarcoma +

Chordoma +

Dedifferentiated Chondrosarcoma +

Diffuse Midline Glioma, H3 K27M-Mutant +

Embryonal Tumor With Multilayered Rosettes, C19MC-Altered +

Embryonal Tumor With Multilayered Rosettes, Not Otherwise Specified +

Ependymoma +

Ependymoma, RELA Fusion-Positive +

Esophageal Squamous Cell Carcinoma +

Fallopian Tube Carcinoma +

Germ Cell Tumor +

Head And Neck Carcinoma +

High-Grade Glioma, NOS +

Histiocytic And Dendritic Cell Neoplasm +

Meningioma +

Neuroblastoma +

Osteosarcoma +

Pineoblastoma +

Primary Peritoneal Carcinoma +

Soft Tissue Sarcoma +

Squamous Cell Lung Carcinoma +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.